Global Cancer Antibody Drug Conjugates Market and Pipeline Insight 2022

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

“Global Cancer Antibody Drug Conjugate Market and Clinical Pipeline Insight 2022” report gives comprehensive insight on various clinical and non-clinical parameters involved in the development of global cancer antibody drug conjugate market. In recent years antibody drug conjugates have emerged as new growth frontier for the companies involved in the research and development of drugs for the treatment of cancer. As per report findings, currently there are 243 antibody drug conjugates in clinical pipeline for the treatment of cancer. Majority of antibody drug conjugates for the treatment of cancer are in preclinical stage followed by research phase clinical trials. There are 6 cancer antibody drug conjugates commercially available in the market. Report helps to analyze the clinical pipeline of antibody drug conjugates by Company, Indication , Mode of Action, Formulation and Phase

Antibody drug conjugates have emerged as new addition to the cancer therapeutic segment which is already overcrowded and consists of numerous competitors. Antibody drug conjugates are based on monoclonal antibodies which delivers drugs in highly targeted manner. Their superior pharmacological profiles have allowed the pharmaceutical companies to commercialize them in highly competitive cancer segment.

Monoclonal antibodies have quite strong hold in cancer market due to high therapeutic efficacy along with minimized side effects. But, it was realized that pharmacological profiles of presently available monoclonal antibodies would not be able to offer benefits in future as cancerous cells develop resistance. Moreover, other benefits like remission, quality of life, morbidity, mortality rates and other parameters are modest at their best. Definitely, monoclonal antibodies are way superior as compared to their traditional counterparts but more improvement is required in order to offer better therapeutic effects. To overcome such issues, concept of antibody drug conjugates was developed; now this concept has been materialized due to availability of advanced technology.

For the cancer where validated predictive biomarkers are available, administration of targeted therapies such as antibody drug conjugates and others have been associated with unprecedented tumor response and clinical benefit. Efforts to design tolerable combination therapies involving antibody-drug conjugate, cancer vaccine, immune checkpoint and kinase inhibition are rational means of maximizing clinical benefit in the targeted delivery of anticancer therapies. The major advantage of using antibody drug conjugates is that it brings together the best characteristics of both antibodies and the cytotoxic potential of chemotherapy. This offers significant opportunity for the market in terms of targeted accumulation of drug in the tumor cell or tissue. Apart from this there are several other benefits of antibody drug conjugates which are driving the market and will be accelerating its share in the upcoming future.

“Global Cancer Antibody Drug Conjugate Market and Clinical Pipeline Insight 2022” report highlights:

Impetus of Antibody Drug Conjugates

Mechanism of Cancer Antibody Drug Conjugates

Global Cancer Antibody Drug Conjugate Clinical Pipeline Overview

Marketed Cancer Antibody Drug Conjugate Clinical Insight

Global Cancer Antibody Drug Conjugate Pipeline by Company, Indication , Mode of Action, Formulation and Phase

Impetus of Antibody Drug Conjugates

1.1 Prologue to Cancer Antibody Drug Conjugate

1.2 The ABCs of ADCs

Structural Entities of Antibody Drug Conjugate

2.1 Rational Design of Antibody Drug Conjugates

2.1.1 Monoclonal Antibody

2.1.2 Linker

2.1.3 Drug Payload

2.2 Aspects of Conjugational Chemistry

Revolutionizing Antibody Drug Conjugates Generation

3.1 First and Second Generation ADCs

3.2 Third Generation ADCs

Mechanism of Cancer Antibody Drug Conjugates

4.1 Sequential Therapeutic Mechanism for Cancer

4.1.1 Selecting an Appropriate Target

4.1.2 Antigen Binding Complex

4.1.3 Antibody Drug Conjugate Internalization

4.2 Approved Antibody Drug Conjugate

Global Cancer Antibody Drug Conjugates Market Overview

Global Cancer Antibody Drug Conjugate Clinical Pipeline Overview

6.1 Phase

6.2 Indication

6.3 Mechanism of Action

6.4 Company

6.5 Formulation

Global Cancer Antibody Drug Conjugates Market Dynamics

7.1 Favorable Market Parameters

7.2 Commercialization Challenges

Global Cancer Antibody Drug Conjugates Market Future Prospects

8.1 Approaching Newer Approaches

8.2 Upcoming Future Market Prospects

Global Cancer Antibody Drug Conjugate Pipeline by Company, Indication and Phase

9.1 Research

9.2 Preclinical

9.3 Clinical

9.4 Phase-I

9.5 Phase-I/II

9.6 Phase-II

9.7 Phase-II/III

9.8 Phase-III

9.9 Preregistration

Marketed Cancer Antibody Drug Conjugate Clinical Insight

10.1 Brentuximab Vedotin (Adcetris)

10.2 Mifamurtide (Junovan and Mepact)

10.3 Gemtuzumab Ozogamicin (Mylotarg)

10.4 Trastuzumab Emtansine (Kadcyla)

10.5 Ibritumomab Tiuxetan (Zevalin and Zevamab)

10.6 Satumomab (OncoScint CR/OV)

Competitive Landscape

11.1 AbbVie

11.2 AbGenomics Corporation

11.3 Biogen Idec

11.4 Biotest

11.5 Bristol-Myers Squibb

11.6 Celldex Therapeutics Inc

11.7 Helix BioPharma

11.8 IBC Pharmaceuticals

11.9 ImmunoGen

11.10 Immunomedics

11.11 Merck

11.12 Millennium

11.13 Nordic Nanovector

11.14 Novartis

11.15 PDL BioPharma

11.16 Progenics Pharmaceuticals

11.17 Roche

11.18 Seattle Genetics

11.19 Stem CentRx

11.20 UCB

11.21 Viventia Biotechnologies

Figure 1-1: Advantages of Antibody Drug Conjugates

Figure 2-1: Detailed Structure of Antibody Drug Conjugate

Figure 2-2: Components of Antibody Drug Conjugates

Figure 2-3: Categorization of the Types of Linkers

Figure 2-4: Conjugation Strategies Adopted for Antibody Drug Conjugate

Figure 3-1: Difference Between First and Second Generation Antibody Drug Conjugate

Figure 3-2: Major Challenges of the Second Generation Antibody Drug Conjugate

Figure 4-1: Mechanism of Antibody Drug Conjugate

Figure 4-2: Mechanism of Brentuximab Vedotin

Figure 4-3: Mechanism of Trastuzumab Emtansine

Figure 5-1: Global - Antibody Drug Conjugates Market (US$ Billion), 2014-2022

Figure 5-2:Global - Adcetris Sales (Million US$), 2016-2022

Figure 5-3: Global - Kadcyla Sales (Million US$), 2016-2022

Figure 5-4: Global - Kadcyla Sales by Region (%), 2016

Figure 6-1: Global - Cancer Antibody Drug Conjugates Pipeline By Phase (%), 2017 till 2022

Figure 6-2: Global - Cancer Antibody Drug Conjugates Pipeline By Phase (Number), 2017 till 2022

Figure 6-3: Global - Cancer Antibody Drug Conjugates Pipeline By Indication (Number), 2017 till 2022

Figure 6-4: Global - Cancer Antibody Drug Conjugates Pipeline By Mode of Action (Number), 2017 till 2022

Figure 6-5: Global - Cancer Antibody Drug Conjugates Pipeline By Company (Number), 2017 till 2022

Figure 6-6: Global - Cancer Antibody Drug Conjugates Pipeline By Formulation (Number), 2017 till 2022

Figure 7-1: Antibody Drug Conjugates Market Favorable Parameters

Figure 7-2: Major Challenges Faced by Antibody Drug Conjugate Market

Figure 11-1:AbGenomics - Clinical Pipeline

Figure 11-2: Celldex - Clinical Pipeline

Figure 11-3: Merck - Clinical Pipeline

Figure 11-4: Millennium - Clinical Pipeline

Figure 11-5: Novartis - Clinical Pipeline

Figure 11-6: Progenics - Clinical Pipeline

Figure 11-7: Roche - Clinical Pipeline

Figure 11-8: Seattle Genetics - Clinical Pipeline

Figure 11-9: Viventia - Clinical Pipepline

Table 4-1: FDA Approved Antibody Drug Conjugate For Cancer

Table 4-2: Some of the Antibody Drug Conjugates under Development

Table 5-1: Drugs for Treatment of HER2-Positive Breast Cancer

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

Global Cancer Antibody Drug Conjugates Market and Pipeline Insight 2022

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

“Global Cancer Antibody Drug Conjugate Market and Clinical Pipeline Insight 2022” report highlights:

Impetus of Antibody Drug Conjugates

Mechanism of Cancer Antibody Drug Conjugates

Global Cancer Antibody Drug Conjugate Clinical Pipeline Overview

Marketed Cancer Antibody Drug Conjugate Clinical Insight

Global Cancer Antibody Drug Conjugate Pipeline by Company, Indication , Mode of Action, Formulation and Phase

Need custom market research solution? We can help you with that too.

About us

Quick links

Contact us

Stay Connected